Evidence map›Paper›PMID 42377444›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2026

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.

Ahmad Kurniawan, Luis Hernandez Cano, Nerea Delgado Mayenco, Sreelakshmi Unnikrishnan, Philip H Elsinga, Inês F Antunes, Erik F J de Vries, Bart Cornelissen

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmad KurniawanDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
Luis Hernandez CanoDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
Nerea Delgado MayencoDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
Sreelakshmi UnnikrishnanDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
Philip H ElsingaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
Inês F AntunesDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
Erik F J de VriesDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands.
Bart CornelissenDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, the Netherlands. b.t.cornelissen@umcg.nl.ORCID http://orcid.org/0000-0001-7581-3303

Funding

Kommission zur Förderung der wissenschaftlichen Forschung 14242LPDP PhD fellowship to AK
6 · The paper itself

Abstract

In recent years, numerous studies have investigated the use of poly (ADP-ribose) polymerase (PARP) inhibitors, labelled with various radionuclides, as agents for targeted radionuclide therapy. This review discusses current advances in studies with radiolabelled PARP inhibitors for targeted radionuclide therapy, focusing on radionuclide selection and (radio)biological properties. We highlight differences between radionuclides and their efficacy in killing cancer cells, while safeguarding healthy tissue. Furthermore, important biomarkers and dosimetry are explored, providing insights and future directions for advancing radiolabelled PARP inhibitors.

Indexed as

Molecular Targeted TherapyNeoplasmsPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRadioisotopesAnimalsHumansRadiopharmaceuticalsPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRadioisotopesRadiopharmaceuticalsAuger electronPARPPARP inhibitorReviewTargeted radionuclide therapy

Identifiers

PMID42377444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.